• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Keratitis - Pipeline Review, H2 2012 Product Image

Keratitis - Pipeline Review, H2 2012

  • ID: 2335151
  • November 2012
  • 41 pages
  • Global Markets Direct

Keratitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Keratitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Keratitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Keratitis. Keratitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Keratitis.
- A review of the Keratitis products under development by companies and universities/research institutes based on information derived from company and READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Keratitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Keratitis 7
Keratitis Therapeutics under Development by Companies 9
Keratitis Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Keratitis Therapeutics – Products under Development by Companies 14
Keratitis Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Keratitis Therapeutics Development 16
Peregrine Pharmaceuticals, Inc. 16
RegeneRx Biopharmaceuticals, Inc. 17
Redox Pharmaceutical Corporation 18
Sirnaomics, Inc. 19
Keratitis – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
RGN-259 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
doxorubicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HO/05/09 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
moxifloxacin hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Riboflavin + Ultraviolet Light A - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
STP-601 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PGN-632 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Keratitis Therapeutics – Drug Profile Updates 34
Keratitis Therapeutics – Discontinued Products 37
Keratitis Therapeutics - Dormant Products 38
Keratitis – Product Development Milestones 39
Featured News & Press Releases 39
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Keratitis, H2 2012 7
Products under Development for Keratitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Peregrine Pharmaceuticals, Inc., H2 2012 16
RegeneRx Biopharmaceuticals, Inc., H2 2012 17
Redox Pharmaceutical Corporation, H2 2012 18
Sirnaomics, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Keratitis Therapeutics – Drug Profile Updates 34
Keratitis Therapeutics – Discontinued Products 37
Keratitis Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Keratitis, H2 2012 7
Products under Development for Keratitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos